Page results
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
A breathing aid that can help keep Covid-19 patients out of intensive care, adapted by mechanical engineers at UCL and clinicians at UCLH working with Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP), has been approved for use in the NHS.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
The UCLH Macmillan Support and Information Service Coffee Morning — a welcoming space for anyone affected by cancer or blood conditions to connect, share experiences, and find support.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
To enable us to provide a quick response when you need it most, we have developed these Frequently Asked Questions (FAQs). We kindly ask you to read through these before contacting our team as you may find the answer to your question here.
-
Patients recovering from coronavirus have spoken movingly about the physical and emotional legacy of the disease.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
Breathing aids developed by engineers at UCL, UCLH and Mercedes-AMG High Performance Powertrains have been delivered to 40 NHS hospitals across the country.
File results
-
FOI/2023/0426 - Maternity services staffing levels
-
FOI/2023/0429 - Breast cancer treatment/ systemic anti-cancer therapies
-
FOI/2023/0430 - Number of operations performed to remove rectal foreign bodies
-
FOI/2023/0437 - Outsourced and insourced procedures for dermatology, endoscopy and gynaecology procedures from 2017/18-2022/23
-
FOI/2023/0438 - Outsourced and insourced procedures dermatology, endoscopy and gynaecological procedures
-
FOI/2023/0448 - Gender, transgender, non-binary guidance/ policy for staff and patients
-
FOI/2023/0422 - Renal cell treatment for carcinoma and melanoma
-
FOI/2023/0449 - Endometriosis pathway
-
FOI2017159 A&E attendances for diabetes, asthma and epilepsy
-
FOI/2023/0445 - Number of people (patients, staff, members of public) stabbed from 2018-2022